Comparison of two methods for carboplatin dosing in children with retinoblastoma

Steven Allen, Matthew Wilson, Amy Watkins, Catherine Billups, Ibrahim Qaddoumi, Barrett H. Haik, Carlos Rodriguez-Galindo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. Patients and Methods. We compared carboplatin doses between two groups of children with retinoblastoma that were treated using a flat dose of 560 mg/m2 or a targeted AUC of 6.5 using a modified Calvert formula. Results. Ninety-eight patients with retinoblastoma received a total of 576 cycles of carboplatin (median 8 cycles). Fifty patients (51%) received a fixed dose per m2, 32 (33%) received a dose based on AUC, 1 patient received fixed dose per kilogram, and in 15 patients a combination AUC and fixed doses was used. The median cumulative carboplatin dose (mg/m2) for patients who received eight cycles using fixed per m2 dosing was 2151.8 (range, 1414.2-2852.0), compared to 1104.1 for nine patients who received eight cycles using Calvert dosing (range, 779.0-1992.7) (P<0.001). For cycles given using AUC, the median percentage of the hypothetical fixed per m2 dose was 70% (range, 48-134%). Younger patients had larger differences. Patients receiving carboplatin based on fixed per m2 dosing were 3.0 times more likely to have a platelet transfusion (95% confidence interval, 1.3-7.3). Conclusions. Carboplatin administration needs to consider the changes in renal function occurring during the first months of life. The use of a targeted AUC provides the most accurate method; however, mg per kg of body weight dosing is a very reliable alternative method.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalPediatric Blood and Cancer
Volume55
Issue number1
DOIs
StatePublished - Jul 15 2010

Fingerprint

Retinoblastoma
Carboplatin
Area Under Curve
Platelet Transfusion
Body Weight
Confidence Intervals
Kidney

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Allen, S., Wilson, M., Watkins, A., Billups, C., Qaddoumi, I., Haik, B. H., & Rodriguez-Galindo, C. (2010). Comparison of two methods for carboplatin dosing in children with retinoblastoma. Pediatric Blood and Cancer, 55(1), 47-54. https://doi.org/10.1002/pbc.22467

Comparison of two methods for carboplatin dosing in children with retinoblastoma. / Allen, Steven; Wilson, Matthew; Watkins, Amy; Billups, Catherine; Qaddoumi, Ibrahim; Haik, Barrett H.; Rodriguez-Galindo, Carlos.

In: Pediatric Blood and Cancer, Vol. 55, No. 1, 15.07.2010, p. 47-54.

Research output: Contribution to journalArticle

Allen, S, Wilson, M, Watkins, A, Billups, C, Qaddoumi, I, Haik, BH & Rodriguez-Galindo, C 2010, 'Comparison of two methods for carboplatin dosing in children with retinoblastoma', Pediatric Blood and Cancer, vol. 55, no. 1, pp. 47-54. https://doi.org/10.1002/pbc.22467
Allen, Steven ; Wilson, Matthew ; Watkins, Amy ; Billups, Catherine ; Qaddoumi, Ibrahim ; Haik, Barrett H. ; Rodriguez-Galindo, Carlos. / Comparison of two methods for carboplatin dosing in children with retinoblastoma. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 1. pp. 47-54.
@article{e3efe8041075417cac874bac07a507b6,
title = "Comparison of two methods for carboplatin dosing in children with retinoblastoma",
abstract = "Background. Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. Patients and Methods. We compared carboplatin doses between two groups of children with retinoblastoma that were treated using a flat dose of 560 mg/m2 or a targeted AUC of 6.5 using a modified Calvert formula. Results. Ninety-eight patients with retinoblastoma received a total of 576 cycles of carboplatin (median 8 cycles). Fifty patients (51{\%}) received a fixed dose per m2, 32 (33{\%}) received a dose based on AUC, 1 patient received fixed dose per kilogram, and in 15 patients a combination AUC and fixed doses was used. The median cumulative carboplatin dose (mg/m2) for patients who received eight cycles using fixed per m2 dosing was 2151.8 (range, 1414.2-2852.0), compared to 1104.1 for nine patients who received eight cycles using Calvert dosing (range, 779.0-1992.7) (P<0.001). For cycles given using AUC, the median percentage of the hypothetical fixed per m2 dose was 70{\%} (range, 48-134{\%}). Younger patients had larger differences. Patients receiving carboplatin based on fixed per m2 dosing were 3.0 times more likely to have a platelet transfusion (95{\%} confidence interval, 1.3-7.3). Conclusions. Carboplatin administration needs to consider the changes in renal function occurring during the first months of life. The use of a targeted AUC provides the most accurate method; however, mg per kg of body weight dosing is a very reliable alternative method.",
author = "Steven Allen and Matthew Wilson and Amy Watkins and Catherine Billups and Ibrahim Qaddoumi and Haik, {Barrett H.} and Carlos Rodriguez-Galindo",
year = "2010",
month = "7",
day = "15",
doi = "10.1002/pbc.22467",
language = "English (US)",
volume = "55",
pages = "47--54",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Comparison of two methods for carboplatin dosing in children with retinoblastoma

AU - Allen, Steven

AU - Wilson, Matthew

AU - Watkins, Amy

AU - Billups, Catherine

AU - Qaddoumi, Ibrahim

AU - Haik, Barrett H.

AU - Rodriguez-Galindo, Carlos

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Background. Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. Patients and Methods. We compared carboplatin doses between two groups of children with retinoblastoma that were treated using a flat dose of 560 mg/m2 or a targeted AUC of 6.5 using a modified Calvert formula. Results. Ninety-eight patients with retinoblastoma received a total of 576 cycles of carboplatin (median 8 cycles). Fifty patients (51%) received a fixed dose per m2, 32 (33%) received a dose based on AUC, 1 patient received fixed dose per kilogram, and in 15 patients a combination AUC and fixed doses was used. The median cumulative carboplatin dose (mg/m2) for patients who received eight cycles using fixed per m2 dosing was 2151.8 (range, 1414.2-2852.0), compared to 1104.1 for nine patients who received eight cycles using Calvert dosing (range, 779.0-1992.7) (P<0.001). For cycles given using AUC, the median percentage of the hypothetical fixed per m2 dose was 70% (range, 48-134%). Younger patients had larger differences. Patients receiving carboplatin based on fixed per m2 dosing were 3.0 times more likely to have a platelet transfusion (95% confidence interval, 1.3-7.3). Conclusions. Carboplatin administration needs to consider the changes in renal function occurring during the first months of life. The use of a targeted AUC provides the most accurate method; however, mg per kg of body weight dosing is a very reliable alternative method.

AB - Background. Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. Patients and Methods. We compared carboplatin doses between two groups of children with retinoblastoma that were treated using a flat dose of 560 mg/m2 or a targeted AUC of 6.5 using a modified Calvert formula. Results. Ninety-eight patients with retinoblastoma received a total of 576 cycles of carboplatin (median 8 cycles). Fifty patients (51%) received a fixed dose per m2, 32 (33%) received a dose based on AUC, 1 patient received fixed dose per kilogram, and in 15 patients a combination AUC and fixed doses was used. The median cumulative carboplatin dose (mg/m2) for patients who received eight cycles using fixed per m2 dosing was 2151.8 (range, 1414.2-2852.0), compared to 1104.1 for nine patients who received eight cycles using Calvert dosing (range, 779.0-1992.7) (P<0.001). For cycles given using AUC, the median percentage of the hypothetical fixed per m2 dose was 70% (range, 48-134%). Younger patients had larger differences. Patients receiving carboplatin based on fixed per m2 dosing were 3.0 times more likely to have a platelet transfusion (95% confidence interval, 1.3-7.3). Conclusions. Carboplatin administration needs to consider the changes in renal function occurring during the first months of life. The use of a targeted AUC provides the most accurate method; however, mg per kg of body weight dosing is a very reliable alternative method.

UR - http://www.scopus.com/inward/record.url?scp=77953269029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953269029&partnerID=8YFLogxK

U2 - 10.1002/pbc.22467

DO - 10.1002/pbc.22467

M3 - Article

VL - 55

SP - 47

EP - 54

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -